250 related articles for article (PubMed ID: 24859340)
21. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
22. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
23. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Sharpe HJ; Pau G; Dijkgraaf GJ; Basset-Seguin N; Modrusan Z; Januario T; Tsui V; Durham AB; Dlugosz AA; Haverty PM; Bourgon R; Tang JY; Sarin KY; Dirix L; Fisher DC; Rudin CM; Sofen H; Migden MR; Yauch RL; de Sauvage FJ
Cancer Cell; 2015 Mar; 27(3):327-41. PubMed ID: 25759019
[TBL] [Abstract][Full Text] [Related]
24. Smoothened variants explain the majority of drug resistance in basal cell carcinoma.
Atwood SX; Sarin KY; Whitson RJ; Li JR; Kim G; Rezaee M; Ally MS; Kim J; Yao C; Chang AL; Oro AE; Tang JY
Cancer Cell; 2015 Mar; 27(3):342-53. PubMed ID: 25759020
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.
Tang Y; Gholamin S; Schubert S; Willardson MI; Lee A; Bandopadhayay P; Bergthold G; Masoud S; Nguyen B; Vue N; Balansay B; Yu F; Oh S; Woo P; Chen S; Ponnuswami A; Monje M; Atwood SX; Whitson RJ; Mitra S; Cheshier SH; Qi J; Beroukhim R; Tang JY; Wechsler-Reya R; Oro AE; Link BA; Bradner JE; Cho YJ
Nat Med; 2014 Jul; 20(7):732-40. PubMed ID: 24973920
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors.
Shin K; Lim A; Zhao C; Sahoo D; Pan Y; Spiekerkoetter E; Liao JC; Beachy PA
Cancer Cell; 2014 Oct; 26(4):521-33. PubMed ID: 25314078
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.
Brown NA; Furtado LV; Betz BL; Kiel MJ; Weigelin HC; Lim MS; Elenitoba-Johnson KS
Blood; 2014 Sep; 124(10):1655-8. PubMed ID: 24982505
[TBL] [Abstract][Full Text] [Related]
28. Activating Smoothened mutations in sporadic basal-cell carcinoma.
Xie J; Murone M; Luoh SM; Ryan A; Gu Q; Zhang C; Bonifas JM; Lam CW; Hynes M; Goddard A; Rosenthal A; Epstein EH; de Sauvage FJ
Nature; 1998 Jan; 391(6662):90-2. PubMed ID: 9422511
[TBL] [Abstract][Full Text] [Related]
29. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive molecular profiling of lung adenocarcinoma.
Cancer Genome Atlas Research Network
Nature; 2014 Jul; 511(7511):543-50. PubMed ID: 25079552
[TBL] [Abstract][Full Text] [Related]
31. Think inside the BOCs: a mechanism underlying medulloblastoma progression.
Lauth M; Toftgard R
Dev Cell; 2014 Oct; 31(1):1-2. PubMed ID: 25313956
[TBL] [Abstract][Full Text] [Related]
32. Smoothened gene alterations in keratocystic odontogenic tumors.
Rui Z; Li-Ying P; Jia-Fei Q; Ying-Ying H; Feng C; Tie-Jun L
Head Face Med; 2014 Sep; 10():36. PubMed ID: 25189937
[TBL] [Abstract][Full Text] [Related]
33. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract][Full Text] [Related]
34. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
[TBL] [Abstract][Full Text] [Related]
35. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
37. The landscape of genetic alterations in ameloblastomas relates to clinical features.
Gültekin SE; Aziz R; Heydt C; Sengüven B; Zöller J; Safi AF; Kreppel M; Buettner R
Virchows Arch; 2018 May; 472(5):807-814. PubMed ID: 29388014
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Hainsworth JD; Meric-Bernstam F; Swanton C; Hurwitz H; Spigel DR; Sweeney C; Burris H; Bose R; Yoo B; Stein A; Beattie M; Kurzrock R
J Clin Oncol; 2018 Feb; 36(6):536-542. PubMed ID: 29320312
[TBL] [Abstract][Full Text] [Related]
39. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology.
Brunner P; Bihl M; Jundt G; Baumhoer D; Hoeller S
Oral Oncol; 2015 Oct; 51(10):e77-8. PubMed ID: 26306423
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
